Oragenics (NYSE:OGEN) is a clinical-stage biotechnology company engaged in the development and commercialization of novel therapeutics to address infectious diseases, immunization and cardiovascular conditions. With a focus on gene therapy, vaccine candidates and antimicrobial agents, Oragenics leverages proprietary platforms to discover and advance biologically based solutions for unmet medical needs. The company’s research and development activities span from early-stage discovery through to clinical trials, positioning it at the forefront of translational biopharmaceutical innovation.
The company’s pipeline includes Generx®, a first-in-class DNA-based gene therapy candidate designed to promote angiogenesis in patients suffering from chronic refractory angina; P-301™, a recombinant quadrivalent influenza vaccine currently in preclinical development; and a suite of novel antimicrobial peptides engineered to target multi-drug resistant bacterial pathogens. Oragenics has also established partnerships and licensing agreements to explore additional applications of its platform technologies in targeted delivery and immune modulation.
Founded in 1997 and headquartered in Tampa, Florida, Oragenics has built a robust network of collaborations with academic research institutions, contract development and manufacturing organizations (CDMOs), and government agencies. The company’s work extends across North America and into select international markets through research collaborations aimed at accelerating the translation of laboratory discoveries into clinical candidates. Over the years, Oragenics has maintained a nimble footprint that enables rapid decision-making and adaptability in response to emerging health challenges.
Oragenics is led by President and Chief Executive Officer Raymond D. Hill, who brings extensive experience in biotech management and strategic partnerships, and Chief Scientific Officer Michael L. Rouse, Ph.D., whose background in molecular biology and gene therapy drives the company’s R&D efforts. Under their leadership, Oragenics seeks to advance its lead candidates through pivotal studies, secure additional collaborative arrangements and ultimately deliver new therapeutic options to patients worldwide.
